Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Cabinet Counselor Koichi Ando Tapped as MHLW Economic Affairs Chief
September 8, 2021
- MHLW to Fund Avigan Program, COVID-19 Drugs from AZ, Shionogi
September 8, 2021
- Japan Strikes Deal for 150 Million Novavax Vaccine Doses, Supply Could Start Early Next Year
September 7, 2021
- Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug Clear PAFSC Panel
September 7, 2021
- Pfizer Vaccine Imports Set to Be Completed in October: Minister
September 7, 2021
- MHLW Panel Backs Takeda’s Cell Therapy Darvadstrocel for Complex Anal Fistulas in CD
September 7, 2021
- Drug Makers Should Conduct Joint Inspections at Contract Manufacturers to Prevent GMP Violations: Expert
September 7, 2021
- Entresto Clears MHLW Panel with Strings Attached, It’s Not a 1st Choice Drug
September 6, 2021
- Japan Govt to Accelerate Discussion on Specific Growth Strategy
September 3, 2021
- Nationwide On-Site Inspections Identify GMP Issues at 9 Generic Plants: MHLW
September 3, 2021
- MHLW Panel to Review Entresto’s Hypertension Indication Again on September 3
September 3, 2021
- Healthcare Spending Totals 42.2 Trillion Yen in FY2020, Showing Record Drop of 1.4 Trillion Yen: MHLW
September 2, 2021
- LDP’s COVID-19 Headquarters Calls for Guidelines on Oral Steroid Administration to Patients Recuperating at Home
September 1, 2021
- Council to Discuss Resuming Active Recommendation of HPV Vaccines: Health Minister
September 1, 2021
- Japan’s Volume-Based Generic Share Reaches 82.1% at End of FY2020, 6 Prefectures Stalling Below 80%: MHLW
September 1, 2021
- MHLW Group Launches Study for Post-Marketing Safety Measures to Boost Global Harmonization, Efficiency
September 1, 2021
- MHLW Panel Shelves Decision on Entresto’s Hypertension Use, Clears Otsuka’s Eczema Med and More
August 31, 2021
- Govt Recognizes Need to Resume HPV Vaccine Discussion: Health Minister
August 31, 2021
- MHLW, Indonesian FDA Ink MOU to Cooperate in Drug Regulations
August 31, 2021
- MHLW to Discuss Ways to Strengthen Stable Supply System of Drugs and Medical Devices: Vice Health Minister
August 30, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…